Skip to main content
No.1 Press Release Service in Korea
Search
Search
Login
Create Account
Services
Contact Us
News
Services
About Us
Contact Us
Korean
News
All News
News by Region
Korea
Overseas
News by Industry
Health
Economy
Education
Finance
Technology
Life Style
Leisure
Culture & Entertainment
Transportation
Society
Heavy Industries
Environment
Government
Services
Why Korea Newswire?
How We Distribute
Services & Pricing
Basic
Standard
Premium
Global
Translation
Press Release Network in Korea
Korean Language
About Us
News
Services
Contact Us
Search
Cancel
Search
Submit Press Release
Latest News
News by Region
Korea
World
News by Industry
Health
Economy
Education
Finance
Technology
Life Style
Leisure
Culture & Entertainment
Transportation
Society
Heavy Industries
Environment
Government
Health News Releases
Today May 17
January 18, 2023 10:10
Takeda Named Global Top Employer for Sixth Consecutive Year
Takeda (TSE:4502/NYSE:TAK) today announced that, for the sixth consecutive year, it was one of only 15 companies to achieve global Top Employer® certification for 2023. In addition to the global certi
January 18, 2023 09:25
Servier and Taiho Oncology Present Overall Survival Data for Trifluridine/Tipiracil (LONSURF®) In Combination With Bevacizumab in Patients With Refractory Metastatic Colorectal Cancer at 2023 ASCO Gastrointestinal Cancers Symposium
Servier and Taiho Oncology, Inc., today announced the release of data from SUNLIGHT, a pivotal Phase 3 global trial evaluating the combination of trifluridine/tipiracil (LONSURF®) and bevacizumab in a
January 18, 2023 09:20
Mental health focus makes Boehringer Ingelheim stand out as Global Top Employer 2023
The Top Employers Institute awarded Boehringer Ingelheim for the third year in succession a “Global Top Employer”, one of the world’s 15 best employers. The certification also highlights the company’s
January 17, 2023 10:15
JUVENESCENCE Appoints Dr Richard Marshall CBE as CEO
Juvenescence has named Dr Richard Marshall CBE as its new CEO, effective 16 January 2023. Dr Marshall succeeds co-founder Dr Gregory Bailey, who will remain on the company’s board as Executive Chairma
January 13, 2023 14:40
Takeda’s EXKIVITY® (mobocertinib) Receives Approval from the NMPA of China, Becoming the First and Only Therapy Available for Patients with EGFR Exon20 Insertion+ NSCLC
Takeda (TSE:4502/NYSE:TAK) today announced that EXKIVITY® (mobocertinib) has been approved by the National Medical Products Administration (NMPA) of China for the treatment of adult patients with loca
January 12, 2023 09:00
Global talent leader WilsonHCG acquires Personify to further expand its healthcare and life sciences talent solutions
WilsonHCG, a global talent leader, has announced the acquisition of Personify, an award-winning recruitment process outsourcing (RPO) provider. Personify specializes in the life sciences, healthcare,
January 11, 2023 10:10
Limb Lengthening Expert Dr. Dror Paley Opens First Clinic in Middle East at UAE’s Burjeel Medical City
As part of its ongoing efforts to focus on complex care and pediatric sub-specialties, Burjeel Holdings, one of the leading private healthcare services providers in the MENA region, in collaboration w
January 10, 2023 13:30
New Study Evaluates the Performance of Masimo SpHb® Noninvasive Spot-Check Hemoglobin in the Emergency Department
Masimo (NASDAQ: MASI) today announced the results of a prospective study published in the American Journal of Emergency Medicine in which Dr. Zohair Ahmed Ali Al Aseri and colleagues at King Saud Univ
January 10, 2023 09:55
Boehringer Ingelheim and 3T Biosciences Join Forces to Develop Next-Generation Cancer Immunotherapies
Boehringer Ingelheim and 3T Biosciences, today announced they have entered into a strategic collaboration and licensing agreement to discover and develop next-generation cancer therapies to address hi
January 10, 2023 09:40
Arrowhead and Takeda Announce Topline Results from SEQUOIA Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency-Associated Liver Disease
Takeda (TSE:4502/NYSE:TAK) and Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced topline results from the Phase 2 SEQUOIA clinical study of investigational fazirsiran (TAK-999/ARO-AAT) for
January 09, 2023 13:30
New Study Finds That Masimo Patient SafetyNet™ Helped Clinicians Reduce CPR Events and Rates, Improve CPR Success Rate, and Reduce Hospital Length of Stay and Mortality
Masimo (NASDAQ: MASI) today announced the findings of a before-and-after study published in PLoS ONE in which Dr. Ahmed Balshi and colleagues at King Saud Medical City in Riyadh, Saudi Arabia, evaluat
January 06, 2023 14:40
Organon Makes Strategic Investment in Claria Medical to Support Development of Investigational Medical Device for Minimally Invasive Hysterectomy
Organon (NYSE: OGN), a global women’s healthcare company, today announced a strategic investment in Claria Medical, Inc. a privately-held company developing an investigational medical device being stu
January 04, 2023 11:43
Biocytogen and Hansoh Pharma Announce an Antibody License Agreement
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, SEHK : 02315) a clinical-stage biotechnology company with a focus on the antibody discovery and development based on its proprietary RenMi
January 04, 2023 10:40
New Prospective Study Evaluates the Accuracy of Masimo SpHb® Noninvasive and Continuous Hemoglobin Monitoring During Elective Cesarean Section
Masimo (NASDAQ: MASI) today announced the findings of a prospective study published in the Egyptian Journal of Anesthesia in which Dr. Mohamed Ibrahim Beleta and colleagues at Cairo University evaluat
December 30, 2022 13:35
Biocytogen Launches RenNano™ Mouse, a Fully Human Heavy Chain Antibody Platform to Accelerate Nanobody Drug Discovery
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) today officially launched its fully human heavy chain antibody platform, RenNano™. RenNano™ is the third member of the RenMic
December 23, 2022 09:25
Merck Announces Collaboration with Mersana Therapeutics to Develop Novel Immunostimulatory Antibody-Drug Conjugates
Merck, a leading science and technology company, today announced a research collaboration and commercial license agreement with Mersana Therapeutics, Inc., Cambridge, Massachusetts, USA to discover no
December 21, 2022 09:45
Boehringer Ingelheim announces appointments to Board of Managing Directors
Boehringer Ingelheim today announces that the Shareholders have appointed Paola Casarosa and Shashank Deshpande to the Board of Managing Directors. They will succeed Michel Pairet, responsible for the
December 20, 2022 10:05
Boehringer Ingelheim and Click Therapeutics expand their existing Collaboration to develop Prescription Digital Therapeutics for Schizophrenia
Boehringer Ingelheim and Click Therapeutics today announced the launch of an expanded collaboration for the development and commercialization of a second prescription-based digital therapeutic (PDT).
December 19, 2022 11:35
Biocytogen Announces FDA Clearance of IND Application for Bispecific Antibody YH008
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) today announced that the US FDA has approved the Investigational New Drug (IND) application for a phase I study of YH008, an
December 16, 2022 16:00
CAS Introducing Transformational Capabilities to Accelerate Life Sciences Innovation
CAS, a division of the American Chemical Society specializing in scientific information solutions, announced several initiatives to once again transform scientific research, and empower more rapid dis
December 16, 2022 11:25
Artilysin®: Fearless Into the Post-antibiotic Era
The WHO has declared antibiotic resistances one of the Top 10 global threats to mankind. To counter this threat, Lysando AG has developed the so-called Artilysin® technology: Novel antimicrobial prote
December 14, 2022 16:45
Takeda to Acquire Late-Stage, Potential Best-in-Class, Oral Allosteric TYK2 Inhibitor NDI-034858 From Nimbus Therapeutics
Takeda (TSE:4502/NYSE:TAK) today announced that it will acquire NDI-034858 from Nimbus Therapeutics. NDI-034858 is an oral, selective allosteric tyrosine kinase 2 (TYK2) inhibitor being evaluated for
December 14, 2022 15:40
Cancellation of remaining publicly held registered shares of Vifor Pharma AG
Regulatory News: AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Vifor Pharma AG (“Vifor”) announced today that the Commercial Court St. Gallen has cancelled (kraftlos erklärt) all remaining publicly
December 14, 2022 14:25
European Commission approves SPEVIGO® (spesolimab) for generalized pustular psoriasis flares
The European Commission (EC) granted a conditional marketing authorization for Boehringer Ingelheim’s spesolimab as first in class treatment for GPP flares in adults.[1] Spesolimab is a novel, selecti
December 14, 2022 10:00
AOP Health presents latest updates on BESREMi® (Ropeginterferon alfa-2b) in Polycythaemia Vera at the American Society of Hematology (ASH) 2022 Annual Meeting
AOP Health announced its latest updates on Ropeginterferon alfa-2b in patients with Polycythaemia Vera (PV) from AOP Health´s CONTINUATION-PV study (Reference Kiladjian et al. ASH 2022) and the LOW-PV
«
18
19
20
21
22
»
25 per page
25 per page
50 per page
75 per page
100 per page
Distribute Your News to
KOREA
The largest press release distribution network in Korea
34,000 journalists
7,000 media outlets
345 industry channel
80,000 subscribers
Get Started
Global PR service
Reach Your Target
Audience in 160 Countries
powered by
Get Started
News by region
Korea
Overseas
News by industry
Health
Economy
Education
Finance
Technology
Life Style
Leisure
Culture & Entertainment
Transportation
Society
Heavy Industries
Environment
Government
Notice